Genus/£GNS

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Genus

Genus PLC, trading under the ticker GNS on the London Stock Exchange, specializes in animal genetics and biotechnology. The company, founded in 1994 and headquartered in Basingstoke, United Kingdom, operates across multiple countries offering genetically superior pig and cattle breeding stock along with state-of-the-art in vitro fertilization products. Genus PLC aims to empower customers in the livestock sector to enhance the efficiency and profitability of their operations by providing innovative genetic solutions and services.

Ticker

£GNS

Primary listing

LSE

Industry

Biotechnology

Employees

3,500

ISIN

GB0002074580

Genus Metrics

BasicAdvanced
£1.3B
-
-£0.06
0.48
£0.32
1.65%

What the Analysts think about Genus

Analyst ratings (Buy, Hold, Sell) for Genus stock.

Bulls say / Bears say

Genus plc received FDA approval for its PRRS Resistant Pig (PRP) gene edit, potentially opening significant revenue streams in the U.S. market. (reuters.com)
The company has initiated a value acceleration program in its bovine business, targeting £10 million in annual cost savings, which could enhance profitability. (investing.com)
Genus's PIC segment achieved growth in royalty revenues and operating profit in North America, Europe, and Latin America, indicating strong market demand. (webull.com)
Genus reported a 5% decrease in revenue and a 31% decrease in adjusted profit before tax in its interim results, reflecting financial challenges. (investing.com)
The company's shares reached a new 52-week low in January 2025, indicating potential investor concerns about its performance. (marketbeat.com)
Genus's operations in China faced challenges, with a 50% profit decline in PIC Asia, highlighting regional market difficulties. (webull.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

Genus Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Genus Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £GNS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs